Cite
El-Akabawy N, Rodriguez M, Ramamurthy R, et al. Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A. Mol Ther Methods Clin Dev. 2020;17:465-477doi: 10.1016/j.omtm.2020.03.001.
El-Akabawy, N., Rodriguez, M., Ramamurthy, R., Rabah, A., Trevisan, B., Morsi, A., George, S., Shields, J., Meares, D., Farland, A., Atala, A., Doering, C. B., Spencer, H. T., Porada, C. D., & Almeida-Porada, G. (2020). Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A. Molecular therapy. Methods & clinical development, 17465-477. https://doi.org/10.1016/j.omtm.2020.03.001
El-Akabawy, Nadia, et al. "Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A." Molecular therapy. Methods & clinical development vol. 17 (2020): 465-477. doi: https://doi.org/10.1016/j.omtm.2020.03.001
El-Akabawy N, Rodriguez M, Ramamurthy R, Rabah A, Trevisan B, Morsi A, George S, Shields J, Meares D, Farland A, Atala A, Doering CB, Spencer HT, Porada CD, Almeida-Porada G. Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A. Mol Ther Methods Clin Dev. 2020 Mar 14;17:465-477. doi: 10.1016/j.omtm.2020.03.001. eCollection 2020 Jun 12. PMID: 32258210; PMCID: PMC7109377.
Copy
Download .nbib